Elsevier

American Heart Journal

Volume 124, Issue 3, September 1992, Pages 768-774
American Heart Journal

Efficacy of lipid profiles in prediction of coronary disease

https://doi.org/10.1016/0002-8703(92)90288-7Get rights and content

Abstract

National guidelines in the United States and Europe have stimulated interest in controlling blood lipid levels to prevent CHD. In this review, the effciency of lipid profiles in predicting CHD has been examined, and total cholesterol, HDL and LDL cholesterol, and triglyceride values have been compared on the basis of 12 to 14 years of surveillance in the Framingham Study. The average value of total cholesterol and LDL cholesterol in patients who had coronary disease was at or below values that are considered dangerous, which indicates the need for more specific and sensitive lipid profiles. Measurement of LDL cholesterol levels predicted CHD only marginally better than measurement of serum total cholesterol. Measurement of triglyceride levels was the weakest predictor. The total cholesterol to HDL cholesterol ratio was the most efficient predictor both in those with apparently safe and those with abnormal cholesterol values. Measurement of HDL cholesterol was the best single lipid predictor and use of this measurement avoids needlessly alarming or falsely reassuring persons at risk for CHD who have high total cholesterol values. Since the risk associated with any serum cholesterol value varies over a 10-fold range depending on coexistent cardiovascular risk factors, these lipid factors must be taken into account in judging the hazards and efficacy of treatment needed. Evidence is available that controlling elevated cholesterol by diet and administration of pharmaceutical agents can reduce the rate of coronary events, slow progression of angiographically visualized lesions, and regress xanthomata. Hence persons at high risk for CHD who have adverse lipid and cardiovascular risk profiles can be efficiently selected for and can benefit from dietary and drug therapy.

References (20)

  • PL Canner et al.

    Fifteen-year mortality in coronary drug project patients: long-term benefit with niacin

    J Am Coll Cardiol

    (1986)
  • J McCormick et al.

    Coronary heart disease is not preventable by population interventions

    Lancet

    (1988)
  • Lowering blood cholesterol to prevent heart disease

    JAMA

    (1985)
  • The Expert Panel

    Report of the National Cholesterol Education Program Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults

    Arch Int Med

    (1988)
  • Consensus Development Panel

    Treatment of hypertriglyceridemia

    JAMA

    (1984)
  • The Lipid Research Clinics Program

    The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in the incidence of coronary heart disease

    JAMA

    (1984)
  • MH Frick et al.

    Helsinki Heart Study Primary Prevention Trial with gemfibrozil in middle-aged men with dyslipidemia

    N Engl J Med

    (1987)
  • DH Blankenhorn et al.

    Beneficial effects of combined colestipol-niacin therapy on coronary atherosclerosis and coronary venous by-pass grafts

    JAMA

    (1987)
  • JF Brengke et al.

    Effects of therapy with Cholestyramine on progression of coronary atherosclerosis. Results of the NHLBI Type II Coronary Intervention Study

    Circulation

    (1984)
  • G Brown et al.

    Regression of coronary artery disease as a result of apolipoprotein B

    N Engl J Med

    (1990)
There are more references available in the full text version of this article.

Cited by (116)

  • A mechanism-based operational definition and classification of hypercholesterolemia

    2022, Journal of Clinical Lipidology
    Citation Excerpt :

    We have chosen the threshold levels of LDLc and non-HDLc in the present document (130 and 160 mg/dL, or 3.4 and 4.1 mmol/L, respectively) in part because NCEP ATP III has already defined them in the past as being predictive of ASCVD risk.15 The knowledge of LDLc and non-HDLc already have proven clinical utility; e.g. they demonstrate excellent sensitivity in screening of hypercholesterolemia of genetic origin in adults;14 and the threshold level chosen for either elevated LDLc or non-HDLc divides the population into lower- and higher-risk groups associated with an approximate doubling of ASCVD risk.16,17 However, the threshold levels of LDLc and non-HDLc chosen to define primary hypercholesterolemia are usually higher (see below), and are situated within the lower range of levels for most genetic hypercholesterolemias in adults.14,18–20

  • High-density lipoproteins: A consensus statement from the National Lipid Association

    2013, Journal of Clinical Lipidology
    Citation Excerpt :

    This ratio has been found to be one of the most powerful lipid measures for predicting CVD events.42,43 Comparing age-adjusted fifth with first quintile lipid CVD risk ratios for the individual lipids and their ratios, it is evident that the total-C/HDL-C and LDL-C/HDL-C ratios are stronger predictors of CHD than the individual lipids that comprise them (Table 2).44 However, knowledge of the individual (total-C and HDL-C) components is important, and in risk assessment and treatment recommendations both are examined as 2 separate, but related, risk factors.45–47

  • Usefulness of lipoprotein ratios in assessing carotid atherosclerosis in Japanese type 2 diabetic patients

    2011, Atherosclerosis
    Citation Excerpt :

    Among these factors, dyslipidemia may play a primary role in the development of atherosclerotic vascular disease and subsequent death due to the disease [1]. Since many observational and interventional studies have demonstrated that low-density lipoprotein (LDL) is the primary atherogenic lipoprotein [2–4] and that high-density lipoprotein (HDL) is the predominant anti-atherosclerotic lipoprotein [5], measurements of total cholesterol (TC), LDL cholesterol (LDL-C), and HDL cholesterol (HDL-C) are widely recommended [1,6]. However, there is a growing evidence suggesting that non-HDL cholesterol (non-HDL-C), defined as the difference between TC and HDL-C to include all atherogenic apoB-containing lipoproteins, is a better tool for assessing the risk of CVD [7–11].

  • Statins in the perioperative period: Take it or leave it?

    2009, Praticien en Anesthesie Reanimation
View all citing articles on Scopus

Supported by The National Heart, Lung and Blood Institute Grant numbers NIH-N01-HV-92922 and NIH-N01-HV-52971; The Charles A. Dana Foundation; Merck, Sharp and Dohme; Pfizer, and Imperial Chemical Industries.

View full text